ORIENT BIO Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
February 14, 2022 at 02:13 am EST
Share
ORIENT BIO Inc. reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was KRW 17,211.51 million compared to KRW 14,134.2 million a year ago. Net income was KRW 939.95 million compared to KRW 4,084.5 million a year ago. Basic earnings per share from continuing operations was KRW 8 compared to KRW 34 a year ago. Basic earnings per share was KRW 8 compared to KRW 34 a year ago.
For the nine months, sales was KRW 768.06 million compared to KRW 973.14 million a year ago. Net income was KRW 3,409.47 million compared to net loss of KRW 5,370.67 million a year ago. Basic earnings per share from continuing operations was KRW 29 compared to basic loss per share from continuing operations of KRW 48 a year ago. Basic earnings per share was KRW 29 compared to basic loss per share of KRW 48 a year ago.
ORIENT BIO Inc. is a Korea-based company engaged in the biotechnology area. The Company produces and supplies laboratory animals, including mice, rats, guinea pigs, hamsters, specific pathogen free (SPF) rabbits, beagles and others. It also provides contract research organization (CRO) services, including CRO safety assessment and CRO new drug development services; medical and library equipment, such as barrier systems, and support services such as rodent surgery services, laboratory diagnostics services, transgenic services, genetic testing services and other services. In addition, along with its subsidiaries, the Company provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines.
ORIENT BIO INC. 
